$1,000 follows their calls into $960
- Win rate
- 43%
- Streak
- 1close
- Best call
- No call read in the last 30 days
- Active calls
- RGNX
Track record building
- Peak #78
- 4 ranked closes
- Longest streak 3
$1,000 follows their calls into $960
Dr. MoneyBall@Dr_MoneyballWe are a few weeks late on $RGNX initiating their rolling BLA for RGX-202 in 3Q26. Certainly not ideal, but they were just guiding for initiation, so as long as they complete their BLA submission in 1Q, it doesn't really matter when they started it. I believe that the data
Dr. MoneyBall@Dr_MoneyballLots of regulatory uncertainty, but this is the key quote from $RGNX press release today: "In recent discussions with FDA, the agency shared that the use of RGX-202 microdystrophin expression as a surrogate endpoint will be based on the correlation analysis with clinical

Dr. MoneyBall@Dr_Moneyball$RGNX closing in on where it was prior to essentially fully derisking their best-in-class DMD asset. The regulatory issue that caused the selloff post data should now be in the rearview mirror given all of the positive news flow from the FDA in the last couple of week. I get
Dr. MoneyBall@Dr_MoneyballIt's official. $RGNX is my favorite child. Green basically every day over the last month. Significantly outperformed $XBI over that period. $ABVX only wishes it could do this type of stuff...
Dr. MoneyBall@Dr_MoneyballOk so $RGNX is $ABVX on steroids right now. pretty much fully derisked. Stock down on a poor raise, but topline data already out and path to $30+ is clear this year. The boat has been loaded.
GIF
Dr. MoneyBall@Dr_Moneyball$RGNX timing of this raise couldn't have gotten much worse. No support from institutions evaluating the raise during the XBI plunge the last week destroyed the stock and now it looks like pricing will be under $10, which again is below where the stock was before they announced